MedX Health Appoints Global Skin Science Leader Dr. Paul Matts as Strategic Advisor
MWN-AI** Summary
MedX Health Corp. (TSXV: MDX), a leader in teledermatology and non-invasive skin analysis, has appointed Dr. Paul J. Matts as a Strategic Advisor. Dr. Matts, a globally recognized expert in skin science and optics, brings over 36 years of experience from his tenure at Procter & Gamble (P&G), where he significantly advanced skin care research and development. As a former R&D Vice President, his innovations contributed to many of P&G's iconic brands, and he received the prestigious Victor Mills Society honor for scientific excellence upon his retirement in 2024.
Dr. Matts is renowned for his expertise in human skin optics and has authored over 65 peer-reviewed articles. He is credited with pioneering MedX's Spectrophotometric Intracutaneous Analysis (SIAscopy®), a groundbreaking technology allowing for non-invasive measurement of skin components crucial for early melanoma detection. Since 1993, he has led the development of standardized global tests for sun protection as the head of various international committees.
Additionally, Dr. Matts is passionate about education, serving as a lecturer and visiting professor at notable institutions and establishing the P&G Better Lives Awards to support students at the London College of Fashion. His humanitarian efforts include co-founding "Action on Podo," which addresses podoconiosis in Ethiopia, successfully treating over 40,000 patients.
John Gevisser, CEO of MedX Health, emphasized Dr. Matts' pivotal role in enhancing the company’s scientific capabilities and advancing its mission to improve skin cancer detection and preventive measures through innovative technology. MedX's SIAscopy® technology, integrated into its DermSecure® platform, is designed to provide accurate, rapid assessments of skin health, marking an important step in accessible health care.
MWN-AI** Analysis
MedX Health Corp. (TSXV: MDX) has positioned itself prominently in the teledermatology market through its innovative technologies. The recent appointment of Dr. Paul J. Matts as a Strategic Advisor underscores the company’s commitment to advancing its research and development capabilities. With Dr. Matts' extensive background in skin science and his pioneering work in developing non-invasive skin assessment technologies, this collaboration could significantly enhance MedX’s competitive advantage in the dermatological healthcare industry.
Investors should view Dr. Matts’ appointment as a pivotal moment for MedX. His expertise in skin optics and his history of successful innovations can accelerate the development of the company’s flagship products, particularly the DermSecure® platform and the Spectrophotometric Intracutaneous Analysis (SIAscopy®) technology. These advancements are aimed at improving early cancer detection, which is increasingly critical given the rise in skin cancer prevalence globally.
Furthermore, Dr. Matts’ background in developing standardized global test methods for sun protection reflects his authority in the industry and could also pave the way for MedX to potentially collaborate with regulatory bodies for new health standards. This type of strategic alliance could enhance the company’s credibility and market reach.
From a financial perspective, potential investors may consider the following: MedX is at the intersection of healthcare and technology, two trends that are increasingly validated by consumer demand and public health needs. As the company leverages its strengthened scientific foundation to expand its technology offerings, it mayexperience significant growth opportunities.
However, investors should remain cautious and conduct thorough due diligence, as the market for medical technology can be volatile, influenced by regulatory changes and competitive pressures. Keeping an eye on MedX Health's performance metrics and market position following this executive change is advised for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MedX Health Corp. (TSXV: MDX), “ MedX ” or the “ Company ”), a global leader in teledermatology and non-invasive skin analysis, today announced the appointment of Dr. Paul J. Matts, internationally recognized skin scientist, biochemist and educator, as Strategic Advisor to the Company.
Dr. Matts joined Procter & Gamble (P&G) in 1988 as a PhD biochemist and then spent more than three decades in the company’s Research & Development (R&D) divisions, where he applied his expertise to develop breakthrough measures of skin condition, optics and health. Across his 36 year career, he drove serial innovation across some of P&G’s most iconic brands in skin care, colour cosmetics, personal cleansing, hand and body care, and was sought out as a consultant for projects across P&G’s other product categories. He retired in 2024 as R&D Vice President and was honoured as a member of P&G’s Victor Mills Society, the company’s most prestigious recognition for scientific innovation.
A global authority on human skin optics, stratum corneum biology, sun protection and the psychology of skin perception, Dr. Matts has authored over 65 peer-reviewed publications, delivered more than 150 keynote presentations worldwide and is widely recognized as a leader in both dermatology and cosmetic science. His pioneering work on MedX’s technology, Spectrophotometric Intracutaneous Analysis (SIAscopy®) enabled, for the first time, the simultaneous, non-invasive measurement of melanin, hemoglobin and collagen, driving powerful new application in both the early detection of malignant melanoma skin cancer and the cosmetic sciences.
Dr. Matts has been a leader in the development of standardized global test methods for sun protection since 1993, at European Trade Association level (as the Chairman of the Cosmetics Europe (CE) Sun Protection Methods Task Force and then the Chairman of the CE Sun Protection Strategic Advisory Group) and at International Standards Organisation level (as the UK expert to the ISOTC217/WG5 working group, that has now developed and deployed 4 new SPF and UVA international standards). He is also an elected Fellow of the Royal Society of Chemistry and the Royal Society of the Arts, reflecting his leadership at the intersection of science, technology and public benefit.
Passionate about education, Dr. Matts has been a Lecturer for the London College of Fashion’s Cosmetic Science Degree and Masters courses since 1993, was appointed Visiting Professor to the UCL School of Pharmacy in 2007 and Visiting Professor to the London College of Fashion in 2010. In 2013, Dr. Matts established the annual P&G Better Lives Awards, recognising and supporting outstanding students across the London College of Fashion. In July 2025, Dr. Matts was recognized with an Honorary Doctorate by the University of the Arts London.
Beyond his academic and industry leadership, Dr. Matts co-founded “Action on Podo” in 2012, a registered Ethiopian non-governmental organization dedicated to eradicating podoconiosis, a devastating, preventable skin disease afflicting over 1.5 million people. Under his leadership, the on-going initiative has now successfully treated more than 40,000 patients.
“MedX is advancing the early detection of skin cancer at scale using its DermSecure® platform, coupled with MedX’s imaging technology (SIAcopy®),” said Dr. Matts. “I am delighted to contribute my experience in skin optics, sun protection and perception science to help accelerate MedX’s mission to reduce the global burden of skin cancer and preventable skin disease.”
John Gevisser, CEO of MedX Health, added: “Dr. Paul Matts is not only one of the world’s foremost authorities on skin science and sun protection, but also an educator and humanitarian who has dedicated his career to improving the lives of others. His expertise will strengthen MedX’s scientific foundation and help advance our goal of delivering accurate, trusted and widely-accessible skin cancer screening and the development of new skin assessment technologies for the health and beauty industry.”
About MedX Health Corp.:
MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy® technology, integrated into the DermSecure® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX’s advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy® , and its secure, cloud-based patient management system, DermSecure® . SIAscopy® is the only technology capable of the simultaneous, non-invasive measurement of the concentration and spatial distribution of melanin, hemoglobin and collagen in the epidermis and dermis of human skin. Visit: https// www.medxhealth.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250908353613/en/
MedX Health Corp.
John Gevisser, CEO- MedX Health Corp.
john.gevisser@medxhealth.com
(+1) 905-670-4428
FAQ**
How will Dr. Paul J. Matts' extensive experience in skin science and optics enhance the technological capabilities of MedX Health Corp. (MDX:CC) and impact its market position in teledermatology?
Considering MedX Health Corp. (MDX:CC) focuses on the early detection of skin cancer, what specific advancements or innovations does Dr. Matts bring that could potentially increase the effectiveness of the DermSecure® platform?
With the promising developments in skin assessment technologies mentioned in the announcement, how does MedX Health Corp. (MDX:CC) plan to leverage Dr. Matts' expertise to expand its product offerings in the health and beauty industry?
Given Dr. Matts' history with standardized global test methods for sun protection, how might his involvement influence regulatory advancements or consumer acceptance of MedX Health Corp.'s (MDX:CC) SIAcopy® technology in various markets?
**MWN-AI FAQ is based on asking OpenAI questions about Medx Health Corp. (TSXVC: MDX:CC).
NASDAQ: MDX:CC
MDX:CC Trading
0.0% G/L:
$0.065 Last:
6,000 Volume:
$0.06 Open:
